BOULDER, Colorado - ArcherDX and PierianDx today announced co-marketing and licensing agreements that will provide enhanced NGS testing capabilities to clinical labs. Under the terms of the agreement, PierianDx will integrate Archer® targeted NGS testing pipelines into the PierianDx Clinical Genomicist Workspace™ (CGW), the leading cloud-based platform that provides clinical labs more streamlined and accurate NGS data analysis, interpretation, and reporting.
Archer’s FusionPlex® and VariantPlex™ target enrichment assays, coupled with its bioinformatics software, Archer Analysis, report known and novel gene fusions, CNVs, point mutations and relative expression levels from NGS libraries.
“Integrating Archer Analysis and the corresponding target enrichment assays into CGW enables PierianDx’s partner laboratories to offer the most comprehensive, clinically relevant results to oncologists,” said PierianDx CEO Ted Briscoe. “Archer’s FusionPlex and VariantPlex assays provide more granular details about CNVs, fusions and point mutations in their patient samples, providing enhanced NGS testing capability to clinical labs seeking a complete solution for their personalized medicine programs.”
“NGS data contains only the primary sequencing information for downstream analysis, and ultimately, reporting of clinically relevant variants in a scalable manner is the desired end result,” said Todd Pollard, Vice President of Global Sales and Support at ArcherDX. “Partnering with PierianDx enables laboratories who use the Archer assays to seamlessly process clinical cases from accessioning to final report using PierianDx’s comprehensive workflow, curated knowledgebase, and partner-sharing network.”
Both companies will work together to market and distribute their products and services globally.
PierianDx enables health systems, academic medical centers and commercial labs to deliver patient-specific diagnosis and treatments based on an individual’s DNA. In use since 2011, and regularly enhanced with new patient, clinical and research data, PierianDx’s proprietary Clinical Genomicist Workspace provides clinical labs more streamlined and accurate analysis, interpretation, and reporting needed to accelerate their personalized medicine programs. PierianDx also recently launched the NGS Gateway Program, a CAP-accredited, CLIA-certified lab that complements PierianDx partners’ in-house NGS testing services.
Clinical Genomicist Workspace™ is a trademark of PierianDX, Inc.
ArcherDX addresses the bottlenecks associated with using NGS in translational research by offering a robust platform for targeted sequencing applications. By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry and easy-to-use, lyophilized reagents, Archer® NGS assays generate highly enriched sequencing libraries to detect gene fusions, point mutations, CNVs and RNA abundance. Complemented by the Archer suite of bioinformatics software, ArcherDX technology dramatically enhances complex mutation identification and discovery.
ArcherDX is headquartered in Boulder, Colorado.
Archer®, FusionPlex®, VariantPlex™ and AMP™ are trademarks of ArcherDX, Inc.
2477 55th Street, Suite 202
Boulder, CO 80301